<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:55:35Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4322824" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4322824</identifier><datestamp>2015-02-17</datestamp><setSpec>crimrheumatology</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Case Rep Rheumatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Case Rep Rheumatol</journal-id>
      <journal-id journal-id-type="publisher-id">CRIRH</journal-id>
      <journal-title-group>
        <journal-title>Case Reports in Rheumatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2090-6889</issn>
      <issn pub-type="epub">2090-6897</issn>
      <publisher>
        <publisher-name>Hindawi Publishing Corporation</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4322824</article-id>
      <article-id pub-id-type="pmcid">PMC4322824</article-id>
      <article-id pub-id-type="pmc-uid">4322824</article-id>
      <article-id pub-id-type="pmid">25692065</article-id>
      <article-id pub-id-type="doi">10.1155/2015/463959</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A New Mutation in Blau Syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zeybek</surname>
            <given-names>Cengiz</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Basbozkurt</surname>
            <given-names>Gokalp</given-names>
          </name>
          <xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
          <xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gul</surname>
            <given-names>Davut</given-names>
          </name>
          <xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Demirkaya</surname>
            <given-names>Erkan</given-names>
          </name>
          <xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gok</surname>
            <given-names>Faysal</given-names>
          </name>
          <xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="I1"><sup>1</sup>Pediatric Nephrology Department, Gulhane Military Medical Academy, Etlik, Kecioren, 06010 Ankara, Turkey</aff>
      <aff id="I2"><sup>2</sup>Pediatrics Department, Gulhane Military Medical Academy, Etlik, Kecioren, 06010 Ankara, Turkey</aff>
      <aff id="I3"><sup>3</sup>Medical Genetics Department, Gulhane Military Medical Academy, Etlik, Kecioren, 06010 Ankara, Turkey</aff>
      <aff id="I4"><sup>4</sup>Pediatric Rheumatology and Nephrology Department, Gulhane Military Medical Academy, Etlik, Kecioren, 06010 Ankara, Turkey</aff>
      <author-notes>
        <corresp id="cor1">*Gokalp Basbozkurt: <email>gokalp_b@yahoo.com</email></corresp>
        <fn fn-type="other">
          <p>Academic Editor: George S. Habib</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <volume>2015</volume>
      <elocation-id>463959</elocation-id>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>9</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>10</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>5</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2015 Cengiz Zeybek et al.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license xlink:href="https://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Blau syndrome is a rare, autosomal dominant, granulomatous autoinflammatory disease. The classic triad of the disease includes recurrent uveitis, granulomatous dermatitis, and symmetrical arthritis. Blau syndrome is related to mutations located at the 16q12.2â13 gene locus. To date, 11 NOD2 gene mutations causing Blau syndrome have been described. Here, we describe a 5-year-old male patient who presented with Blau syndrome associated with a novel sporadic gene mutation that has not been reported previously.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Background</title>
      <p>Blau syndrome (OMIM 186580) is a rare, autosomal dominant (AD), and granulomatous autoinflammatory disease first described by Blau in 1985 [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. The classic triad of the disease includes recurrent uveitis, granulomatous dermatitis, and symmetrical arthritis; however, all symptoms may not appear concurrently [<xref rid="B2" ref-type="bibr">2</xref>]. Blau syndrome is associated with mutations located at the 16q12.2â13 gene locus [<xref rid="B3" ref-type="bibr">3</xref>]. The NOD2 gene is associated with the innate immune system [<xref rid="B4" ref-type="bibr">4</xref>]. To date, 11 NOD2 gene mutations causing Blau syndrome have been described. Moreover, seven NOD2 mutations that may be associated Blau syndrome have been identified [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. Here, we describe a novel sporadic gene mutation causing Blau syndrome that has not been reported previously.</p>
    </sec>
    <sec id="sec2">
      <title>2. Case</title>
      <p>A 5-year-old male was initially admitted to our clinic at 5 months of age with a maculopapular erythematous rash over his entire body (Figures <xref ref-type="fig" rid="fig1">1</xref> and <xref ref-type="fig" rid="fig2">2</xref>). The patient's family history revealed no inherited familial disease. The patient's skin lesions persisted for 1 year and disappeared spontaneously. At the age of 3 years, the patient visited our unit with swelling of the dorsum of the hands (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Physical examination revealed swelling, pain, limitation of movement, and increased warmth in both hands, but no rash. The laboratory results were as follows: hemoglobin 12.7âg/dL, white blood cell count 12600/mm<sup>3</sup>, platelet count 446000/mm<sup>3</sup>, erythrocyte sedimentation rate 15âmm/h, C-reactive protein 4.2âmg/dL (normal range, 0â0.5), rheumatoid factor 6âIU/mL (normal level, &lt;16), and antinuclear antibody negative. Ultrasonography of the swelling, performed at another facility, revealed tenosynovial cysts. At follow-up after a 2-month period without treatment, we detected swelling of the dorsum of both feet. Four months after the first swelling appeared, the patient presented at our hospital with symmetrical arthritis of both knees. We diagnosed the patient with systemic or RF-negative polyarticular juvenile idiopathic arthritis (JIA) and administered ibuprofen, prednisolone, and subcutaneous methotrexate. Four months after treatment commenced, we detected symmetrical arthritis of both wrists and ankles. We discontinued the initial treatment and began etanercept treatment. However, the patient developed etanercept-induced fever 3 weeks after initiation of the drug treatment, and the etanercept administration was therefore ceased. During follow-up at 5 years of age, the ophthalmological examination revealed granulomatous anterior uveitis in the patient's right eye, as indicated by large precipitates in the anterior chamber and nodules in the iris. Thus, the presence of skin lesions, granulomatous ophthalmologic inflammation, and the NOD2 gene mutation ruled out the diagnosis of JIA. Taken together, the clinical and laboratory findings of our case suggested a diagnosis of Blau syndrome. Genetic studies were run to investigate the NOD2 gene mutation. The results showed only a P507S mutation; however, a novel heterozygote mutation P507S (c.1519C&gt;T) in the fourth exon of the NOD2 gene was revealed. Analysis of the protein variant revealed that the mutation was p.Pro507Ser.<italic> In silico</italic> assessment (SIFT, Mutation Taster, and Polyphen) of the mutation indicated a strong association with Blau syndrome. We found no data to indicate that this mutation caused NF-kappa B hyperactivation. This heterozygous NOD2 gene mutation has not been reported previously.</p>
      <p>Although Blau syndrome is an AD inherited disease, the parents of the patient were healthy. Blau syndrome resulting from<italic> de novo</italic> mutations may present sporadically [<xref rid="B7" ref-type="bibr">7</xref>], and we believe a<italic> de novo</italic> mutation caused the Blau syndrome in our case. The symptoms of the disease tend to appear before the age of 3 or 4 years [<xref rid="B8" ref-type="bibr">8</xref>]. The initial symptoms are primarily cutaneous and articular findings, as was the case in our patient [<xref rid="B9" ref-type="bibr">9</xref>â<xref rid="B11" ref-type="bibr">11</xref>]. Ocular findings typically appear between the ages of 7 and 12 years [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Patients presenting with joint findings are often misdiagnosed as JIA in the absence of ocular and cutaneous findings. Granulomatous inflammation of the hand dorsum may cause tenosynovial cysts, as we observed in our case [<xref rid="B5" ref-type="bibr">5</xref>]. No specific cutaneous findings are associated with Blau syndrome, and most types of skin findings may occur [<xref rid="B5" ref-type="bibr">5</xref>]. Skin lesions may recover spontaneously after several months, as occurred in our case [<xref rid="B5" ref-type="bibr">5</xref>]. The histologic examination of the skin lesions revealed noncaseating granulomatous disease [<xref rid="B5" ref-type="bibr">5</xref>]. The eye lesions most frequently associated with Blau syndrome are recurrent anterior uveitis and panuveitis [<xref rid="B13" ref-type="bibr">13</xref>], which are serious and can cause blindness [<xref rid="B5" ref-type="bibr">5</xref>]. Steroids are the principle treatment for Blau syndrome. If steroid therapy is ineffective or causes adverse effects, biological agents including tumor necrosis factor inhibitors and interleukin-1 receptor antagonists may be used [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B14" ref-type="bibr">14</xref>â<xref rid="B17" ref-type="bibr">17</xref>]. The response to these agents has been found to be variable. Thalidomide treatment has been reported to be an alternative treatment option [<xref rid="B18" ref-type="bibr">18</xref>]. Our patient did not achieve remission with steroid therapy; thus, he is currently receiving canakinumab therapy.</p>
    </sec>
    <sec id="sec3">
      <title>3. Conclusion</title>
      <p>To date, 18 different NOD2 mutations associated with Blau syndrome have been identified. Here, we described a<italic> de novo</italic> mutation causing Blau syndrome that has not been reported previously.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>JIA:</term>
          <def>
            <p>Juvenile idiopathic arthritis</p>
          </def>
        </def-item>
        <def-item>
          <term>AD:</term>
          <def>
            <p>Autosomal dominant.</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <sec sec-type="conflict">
      <title>Conflict of Interests</title>
      <p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Punzi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Gava</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Galozzi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sfriso</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome</article-title>
          <source>
            <italic>Best Practice &amp; Research: Clinical Rheumatology</italic>
          </source>
          <year>2011</year>
          <volume>25</volume>
          <issue>5</issue>
          <fpage>703</fpage>
          <lpage>714</lpage>
          <pub-id pub-id-type="doi">10.1016/j.berh.2011.10.017</pub-id>
          <pub-id pub-id-type="pmid">22142748</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blau</surname>
              <given-names>E. B.</given-names>
            </name>
          </person-group>
          <article-title>Familial granulomatous arthritis, iritis, and rash</article-title>
          <source>
            <italic>The Journal of Pediatrics</italic>
          </source>
          <year>1985</year>
          <volume>107</volume>
          <issue>5</issue>
          <fpage>689</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="doi">10.1016/s0022-3476(85)80394-2</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0022213722</pub-id>
          <pub-id pub-id-type="pmid">4056967</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tromp</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kuivaniemi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Raphael</surname>
              <given-names>S.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16</article-title>
          <source>
            <italic>The American Journal of Human Genetics</italic>
          </source>
          <year>1996</year>
          <volume>59</volume>
          <issue>5</issue>
          <fpage>1097</fpage>
          <lpage>1107</lpage>
          <pub-id pub-id-type="other">2-s2.0-19244364857</pub-id>
          <pub-id pub-id-type="pmid">8900239</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Inohara</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Benito</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>F. F.</given-names>
            </name>
            <name>
              <surname>Yamaoka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>NÃºÃ±ez</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-<italic>Îº</italic>B</article-title>
          <source>
            <italic>The Journal of Biological Chemistry</italic>
          </source>
          <year>2001</year>
          <volume>276</volume>
          <issue>7</issue>
          <fpage>4812</fpage>
          <lpage>4818</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.m008072200</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0035895992</pub-id>
          <pub-id pub-id-type="pmid">11087742</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sfriso</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Caso</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tognon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Galozzi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gava</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Punzi</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Blau syndrome, clinical and genetic aspects</article-title>
          <source>
            <italic>Autoimmunity Reviews</italic>
          </source>
          <year>2012</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>44</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="other">2-s2.0-84866874147</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.autrev.2012.07.028</pub-id>
          <pub-id pub-id-type="pmid">22884558</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chauhan</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Michet</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>A case of Blau syndrome</article-title>
          <source>
            <italic>Case Reports in Rheumatology</italic>
          </source>
          <year>2014</year>
          <volume>2014</volume>
          <fpage>3</fpage>
          <pub-id pub-id-type="publisher-id">216056</pub-id>
          <pub-id pub-id-type="doi">10.1155/2014/216056</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pillai</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sobrin</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Blau syndrome-associated uveitis and the <italic>NOD2</italic> gene</article-title>
          <source>
            <italic>Seminars in Ophthalmology</italic>
          </source>
          <year>2013</year>
          <volume>28</volume>
          <issue>5-6</issue>
          <fpage>327</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="doi">10.3109/08820538.2013.825285</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84886422277</pub-id>
          <pub-id pub-id-type="pmid">24010719</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rybicki</surname>
              <given-names>B. A.</given-names>
            </name>
            <name>
              <surname>Maliarik</surname>
              <given-names>M. J.</given-names>
            </name>
            <name>
              <surname>Bock</surname>
              <given-names>C. H.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Blau syndrome gene is not a major risk factor for sarcoidosis</article-title>
          <source>
            <italic>Sarcoidosis Vasculitis and Diffuse Lung Disease</italic>
          </source>
          <year>1999</year>
          <volume>16</volume>
          <issue>2</issue>
          <fpage>203</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="other">2-s2.0-0032862746</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>M. L.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>C. D.</given-names>
            </name>
          </person-group>
          <article-title>Blau syndrome and related genetic disorders causing childhood arthritis</article-title>
          <source>
            <italic>Current Rheumatology Reports</italic>
          </source>
          <year>2005</year>
          <volume>7</volume>
          <issue>6</issue>
          <fpage>427</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="doi">10.1007/s11926-005-0046-3</pub-id>
          <pub-id pub-id-type="other">2-s2.0-33645850142</pub-id>
          <pub-id pub-id-type="pmid">16303101</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>RosÃ©</surname>
              <given-names>C. D.</given-names>
            </name>
            <name>
              <surname>Wouters</surname>
              <given-names>C. H.</given-names>
            </name>
            <name>
              <surname>Meiorin</surname>
              <given-names>S.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pediatric granulomatous arthritis: an international registry</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>2006</year>
          <volume>54</volume>
          <issue>10</issue>
          <fpage>3337</fpage>
          <lpage>3344</lpage>
          <pub-id pub-id-type="doi">10.1002/art.22122</pub-id>
          <pub-id pub-id-type="other">2-s2.0-33750345391</pub-id>
          <pub-id pub-id-type="pmid">17009307</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>ArÃ³stegui</surname>
              <given-names>J. I.</given-names>
            </name>
            <name>
              <surname>Arnal</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Merino</surname>
              <given-names>R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>
<italic>NOD2</italic> gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>2007</year>
          <volume>56</volume>
          <issue>11</issue>
          <fpage>3805</fpage>
          <lpage>3813</lpage>
          <pub-id pub-id-type="doi">10.1002/art.22966</pub-id>
          <pub-id pub-id-type="other">2-s2.0-36048981805</pub-id>
          <pub-id pub-id-type="pmid">17968944</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okafuji</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Nishikomori</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kanazawa</surname>
              <given-names>N.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>2009</year>
          <volume>60</volume>
          <issue>1</issue>
          <fpage>242</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="doi">10.1002/art.24134</pub-id>
          <pub-id pub-id-type="other">2-s2.0-58249095950</pub-id>
          <pub-id pub-id-type="pmid">19116920</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurokawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ohta</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation</article-title>
          <source>
            <italic>Ophthalmology</italic>
          </source>
          <year>2003</year>
          <volume>110</volume>
          <issue>10</issue>
          <fpage>2040</fpage>
          <lpage>2044</lpage>
          <pub-id pub-id-type="doi">10.1016/s0161-6420(03)00717-6</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0141747229</pub-id>
          <pub-id pub-id-type="pmid">14522785</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raphael</surname>
              <given-names>S. A.</given-names>
            </name>
            <name>
              <surname>Blau</surname>
              <given-names>E. B.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W. H.</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>S. H.</given-names>
            </name>
          </person-group>
          <article-title>Analysis of a large kindred with Blau syndrome for HLA, autoimmunity, and sarcoidosis</article-title>
          <source>
            <italic>The American Journal of Diseases of Children</italic>
          </source>
          <year>1993</year>
          <volume>147</volume>
          <issue>8</issue>
          <fpage>842</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="other">2-s2.0-0027227934</pub-id>
          <pub-id pub-id-type="pmid">8394645</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simonini</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Caputo</surname>
              <given-names>R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>2013</year>
          <volume>65</volume>
          <issue>2</issue>
          <fpage>513</fpage>
          <lpage>518</lpage>
          <pub-id pub-id-type="doi">10.1002/art.37776</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84873814538</pub-id>
          <pub-id pub-id-type="pmid">23124805</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>la Torre</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Lapadula</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cantarini</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lucherini</surname>
              <given-names>O. M.</given-names>
            </name>
            <name>
              <surname>Iannone</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature</article-title>
          <source>
            <italic>Clinical Rheumatology</italic>
          </source>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1007/s10067-014-2493-6</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84892448753</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>T. M.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Kurz</surname>
              <given-names>P.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The NOD2 defect in Blau Syndrome does not result in excess interleukin-1 activity</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>2009</year>
          <volume>60</volume>
          <issue>2</issue>
          <fpage>611</fpage>
          <lpage>618</lpage>
          <pub-id pub-id-type="doi">10.1002/art.24222</pub-id>
          <pub-id pub-id-type="other">2-s2.0-59649127380</pub-id>
          <pub-id pub-id-type="pmid">19180500</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yasui</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yashiro</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tsuge</surname>
              <given-names>M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau Syndrome: its possible action and mechanism</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>2010</year>
          <volume>62</volume>
          <issue>1</issue>
          <fpage>250</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1002/art.25035</pub-id>
          <pub-id pub-id-type="other">2-s2.0-74849116666</pub-id>
          <pub-id pub-id-type="pmid">20039400</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="fig1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Maculopapular erythematous rash at 5 months of age.</p>
      </caption>
      <graphic xlink:href="CRIRH2015-463959.001"/>
    </fig>
    <fig id="fig2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Maculopapular erythematous rash at 5 months of age.</p>
      </caption>
      <graphic xlink:href="CRIRH2015-463959.002"/>
    </fig>
    <fig id="fig3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Swelling of the dorsum of the hands at 3 years of age.</p>
      </caption>
      <graphic xlink:href="CRIRH2015-463959.003"/>
    </fig>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>